Compare BODI & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BODI | PDSB |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | 270 | 10 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 62.0M |
| IPO Year | N/A | 2015 |
| Metric | BODI | PDSB |
|---|---|---|
| Price | $10.18 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $9.00 |
| AVG Volume (30 Days) | 66.3K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $0.51 |
| 52 Week High | $16.87 | $1.90 |
| Indicator | BODI | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 46.64 |
| Support Level | $9.54 | $0.88 |
| Resistance Level | $11.11 | $1.12 |
| Average True Range (ATR) | 0.92 | 0.14 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 33.91 | 10.42 |
The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers. a results-oriented company at the intersection of wellness, technology, and media. The company developed one of the original fitness digital streaming platforms with an extensive library of content containing streaming programs and streaming videos. Company products include Digital Subscriptions, Nutritional Products, and Connected Fitness Products, where the majority of revenue is from Digital Subscriptions. The Company has one operating and reporting segment. Geographically operates in the USA and the rest of the world, with maximum revenue from the United States.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.